Principles of Pelvic Organ Prolapse Repair
Prolapse treatment should address the patient's symptoms and functional goals while accounting for anatomy, health, previous surgery and preferences about uterine preservation, vaginal intercourse and mesh. A POP-Q stage alone does not determine the need for surgery.[1] This page covers selection and counseling; individual operations are linked from the prolapse repair atlas.
Assessment and Treatment Selection
- Document bulge symptoms, urinary emptying and leakage, bowel function, sexual function and the patient's priorities. Examine all compartments using POP-Q, assess pelvic floor contraction and vaginal tissue, and exclude other pathology. Investigate pain, obstructed defecation or symptoms that do not match the examination. Measure postvoid residual when voiding dysfunction or recurrent UTI is present.[1]
- Discuss observation, pelvic floor therapy, pessary and surgery. Observation is reasonable for uncomplicated prolapse that is not bothersome; urinary dysfunction or other complications still need assessment. A pessary trial is an option, not a prerequisite for surgery. NICE recommends offering surgery when symptoms persist with nonsurgical management or the patient declines it.[1]
- Agree on what success means: relief of bulge and functional symptoms, acceptable recovery and sexual function, and avoidance of further treatment. Anatomic recurrence, bothersome recurrence and reoperation are different outcomes; trial percentages must be interpreted with their definition and follow-up interval.[2][9]
Nonsurgical Management
Pessaries provide a reversible treatment option, either alone or with pelvic floor muscle training. Fitting may require several sizes or types; anatomy, comfort, retention, self-management and intercourse preferences guide selection. Successful initial fitting is different from long-term use or symptom improvement. Explain discharge, bleeding, expulsion and removal difficulties, and establish a removal and follow-up plan.[1]
In the PEOPLE randomized trial, 440 women with symptomatic stage 2 or greater prolapse were assigned to initial pessary treatment or surgery. At 24 months, 132/173 pessary-group respondents (76.3%) and 132/162 surgery-group respondents (81.5%) reported substantial improvement. Pessary treatment did not meet the prespecified noninferiority criterion of 10 percentage points; 118/218 women assigned to pessary crossed over to surgery. Both options can help, but these results do not establish equal effectiveness or a universal pessary success rate.[8]
Supervised pelvic floor muscle training for at least 16 weeks is a first option for symptomatic stage 1–2 prolapse in NICE guidance. Address constipation and relevant lifestyle factors. Vaginal estrogen can be considered for associated menopausal genitourinary symptoms; it is not an anatomic prolapse repair.[1]
A 2025 placebo-controlled trial randomized 420 postmenopausal women already successfully fitted with a ring pessary with support. Conjugated estrogen cream did not improve the 12-month combined endpoint of pessary continuation and substantial improvement: 181/208 (87.0%) versus 176/203 (86.7%); difference 0.3 percentage points (95% CI −6.2 to 6.9). Some pessary-related adverse events were less frequent with estrogen, but these were secondary findings. Do not promise better continuation or prescribe estrogen solely as a proven way to improve pessary success.[7]
Choosing a Repair
| Decision | Practical approach |
|---|---|
| Apical prolapse | Document how apical support will be restored. Choose a vaginal native-tissue suspension or abdominal/laparoscopic/robotic sacral suspension according to anatomy, operative risk, mesh preferences and expertise; address associated wall defects.[1][2][9] |
| Anterior or posterior wall prolapse | Native-tissue vaginal repair is the standard option in NICE guidance. Evaluate coexisting apical loss and urinary/bowel symptoms rather than selecting a repair from the visible wall defect alone.[1] |
| Uterine prolapse | Discuss hysteropexy and hysterectomy with an apical-support plan. Consider uterine/cervical pathology, bleeding, future surveillance and the patient's preference.[1][4][5] |
| Obliterative surgery | Discuss colpocleisis with patients who do not intend future penetrative vaginal intercourse, particularly when health conditions increase reconstructive operative risk. Explain the permanent change in vaginal access and function.[1] |
Age, BMI, POP-Q stage or prior recurrence can inform counseling, but they are not stand-alone numerical thresholds that automatically select sacrocolpopexy. Mesh exposure, visceral injury, recovery, recurrent symptoms and possible further surgery should be discussed for the actual proposed procedure.[1][2]
Native-tissue apical suspension: E-OPTIMAL
The E-OPTIMAL trial compared bilateral uterosacral ligament suspension (ULS) with unilateral sacrospinous ligament fixation (SSLF). The original trial enrolled women with SUI and planned concomitant retropubic midurethral slings; 374 were originally randomized, 285 entered extended follow-up and 244 completed it. At five years, modeled first composite failure was 61.5% after ULS versus 70.3% after SSLF; adjusted difference −8.8 percentage points (95% CI −24.2 to 6.6). This did not establish superiority or equivalence.[9]
The endpoint counted specified anatomic descent, bothersome bulge or retreatment, and a participant remained a failure after first meeting a criterion. Symptoms remained improved despite rising composite failure. Choose between ULS and SSLF with their different anatomic and complication considerations; do not summarize the trial as identical success or safety.[9]
Post-hysterectomy vault prolapse: ASPIRe
ASPIRe (Menefee 2024) randomized 376 women with symptomatic vault prolapse after total hysterectomy; 360 underwent a study operation. Modeled 36-month composite failure was 28% with sacrocolpopexy, 29% with transvaginal mesh and 43% with vaginal native-tissue repair. Failure meant retreatment, prolapse beyond the hymen or bothersome bulge.[2]
Sacrocolpopexy was superior to native-tissue repair (adjusted HR 0.57; 99% CI 0.33–0.98). Transvaginal mesh did not meet the trial's superiority threshold versus native tissue. Its noninferiority comparison with sacrocolpopexy used a per-protocol population: HR 1.05, one-sided 97% upper confidence bound 1.65, below the prespecified margin of 1.93. Noninferiority under that margin does not establish equivalence.[2]
Most failures were anatomic; actual repeat prolapse surgery was much less frequent. Apical mesh exposure occurred in 4/120 sacrocolpopexy patients and 6/115 transvaginal-mesh patients. Variable follow-up, missing pandemic-era examinations and concomitant repairs limit interpretation. ASPIRe studied post-hysterectomy vault repair, not uterine preservation, and its Uphold LITE transvaginal product is no longer marketed in the US.[2][11]
For primary uterovaginal prolapse when hysterectomy is chosen, see the September 2026 U-POP review and its study-design limits.
Mesh and Graft Counseling
Separate the indication and implantation route. No FDA-approved surgical mesh product for transvaginal POP repair is currently marketed in the United States. Abdominal sacrocolpopexy mesh and mesh slings for SUI are distinct uses. Historical transvaginal-mesh trial results do not establish current product availability or justify applying their complication rates to another route.[11]
The 2026 anterior-compartment Cochrane review included 41 RCTs and 4,531 women, with searches through April 2024. At one to two years, native-tissue repair had more anatomic recurrence than permanent transvaginal mesh (RR 3.21, 95% CI 2.27–4.55; low certainty), and probably more prolapse awareness and repeat prolapse surgery. These are separate endpoints; the often-quoted 29–58% versus 13% is an illustrative absolute-risk translation, not pooled observed rates. Many tested products have been withdrawn. Biological grafts may improve anatomic recurrence without demonstrated improvement in awareness or repeat prolapse surgery. These findings do not establish a routine indication for vaginal mesh or graft augmentation.[3]
For posterior vaginal wall repair, NICE recommends repair without mesh. Investigate obstructed defecation or fecal incontinence separately when present; the choice of repair must reflect the patient's symptoms and anatomy.[1]
Uterine Preservation and Hysterectomy
Uterine preservation is a reasonable option for an appropriately evaluated patient who prefers it. The comparison depends on the specific suspension and route, not simply whether the uterus is removed.[1]
The Ruffolo 2025 meta-analysis concerned vaginal native-tissue operations. It found no clear difference in several recurrence and patient-reported outcomes, with perioperative advantages for hysteropexy; it cannot establish reduced sacrocolpopexy mesh exposure. Brennand 2025 was a prospective, self-selected cohort of 321 women, not a randomized trial. Its lower adjusted one-year recurrence with uterine preservation supports counseling but does not prove causal superiority or equivalent long-term outcomes.[4][5]
When hysterectomy accompanies sacral suspension, decide between total and supracervical hysterectomy using uterine/cervical findings, bleeding and surveillance preferences, operative factors and the applicable mesh evidence. Cervical retention should not be presented as universally protective or obligatory. See Supracervical Hysterectomy for the evidence and tradeoffs.
Continence and Operative Safety
Assess symptomatic SUI, leakage unmasked by prolapse reduction, and emptying dysfunction before deciding on a concomitant continence procedure. Testing should answer a management question. NICE recommends multichannel cystometry before planned SUI surgery when anterior/apical prolapse, voiding dysfunction, unclear incontinence type or urge-predominant mixed incontinence, or prior SUI surgery is present; this is not a mandate for urodynamics before every prolapse operation.[1]
The 2026 continence Cochrane review supports discussing concomitant MUS for symptomatic or occult SUI. For occult SUI, postoperative SUI was reduced (RR 0.38, 95% CI 0.26–0.55; five studies, 369 women; moderate certainty), while adverse-effect estimates remain less certain. A staged procedure is also feasible. For stress-continent women, the evidence differs by operation and is less consistent; a prophylactic continence procedure should not be an automatic part of prolapse repair.[6]
In CARE, adding Burch during abdominal sacrocolpopexy reduced the corrected three-month composite SUI endpoint from 57.4% to 33.6%. This combined symptoms, stress testing or treatment; the 2016 correction supersedes the original values. Do not merge CARE's abdominal Burch estimates with vaginal-repair sling trials. NICE takes a more restrictive position, recommending against prophylactic continence surgery when incontinence is absent. See the Burch evidence discussion for procedure-specific counseling.[1][6][10]
Intraoperative cystoscopy: the AUGS consensus recommends it during prolapse reconstructive surgery except isolated posterior-compartment repair, with inspection for bladder/urethral injury and confirmation of ureteral efflux. A normal examination does not exclude every injury, including delayed thermal injury.[12]
Arrange postoperative assessment of symptoms, examination findings and complications. NICE includes a six-month vaginal examination, checking for exposure when mesh was used, and access to reassessment for recurrent symptoms or suspected complications.[1]
References
1. National Institute for Health and Care Excellence. Urinary incontinence and pelvic organ prolapse in women: management. NG123. 2019; current recommendations, sections 1.3 and 1.6–1.9. Recommendations.
2. Menefee SA, Richter HE, Myers D, et al. Apical suspension repair for vaginal vault prolapse: a randomized clinical trial. JAMA Surg. 2024;159:845–855. doi:10.1001/jamasurg.2024.1206. ASPIRe; corrected July 10, 2024.
3. Christmann-Schmid C, Baessler K, Yeung E, et al. Surgery for women with anterior compartment prolapse. Cochrane Database Syst Rev. 2026;4:CD004014. doi:10.1002/14651858.CD004014.pub7.
4. Ruffolo AF, Salvatore S, Torella M, et al. The uterus debate in vaginal native tissue repair for pelvic organ prolapse: hysteropexy versus hysterectomy—a systematic review and meta-analysis. Maturitas. 2025;203:108755. doi:10.1016/j.maturitas.2025.108755.
5. Brennand EA, Scime NV, Huang B, et al. Hysterectomy versus uterine preservation for pelvic organ prolapse surgery: a prospective cohort study. Am J Obstet Gynecol. 2025;232:461.e1–461.e20. doi:10.1016/j.ajog.2024.10.021.
6. Baessler K, Christmann-Schmid C, Haya N, et al. Surgery for women with pelvic organ prolapse with or without stress urinary incontinence. Cochrane Database Syst Rev. 2026;2:CD013108. doi:10.1002/14651858.CD013108.pub2.
7. Zhou Y, Yin R, Zhang Y, et al. Effects of intravaginal conjugated oestrogen on pessary continuation for pelvic organ prolapse: multicentre, randomised, double blind, placebo controlled trial. BMJ. 2025;389:e084418. doi:10.1136/bmj-2025-084418.
8. van der Vaart LR, Vollebregt A, Milani AL, et al. Effect of pessary vs surgery on patient-reported improvement in patients with symptomatic pelvic organ prolapse: a randomized clinical trial. JAMA. 2022;328:2312–2323. doi:10.1001/jama.2022.22385.
9. Jelovsek JE, Barber MD, Brubaker L, et al. Effect of uterosacral ligament suspension vs sacrospinous ligament fixation with or without perioperative behavioral therapy for pelvic organ vaginal prolapse on surgical outcomes and prolapse symptoms at 5 years in the OPTIMAL randomized clinical trial. JAMA. 2018;319:1554–1565. doi:10.1001/jama.2018.2827.
10. Brubaker L, et al. Abdominal sacrocolpopexy with Burch colposuspension: author correction letter. N Engl J Med. 2016;374:2295. doi:10.1056/NEJMc1605817.
11. US Food and Drug Administration. Urogynecologic surgical mesh implants. Current regulatory overview.
12. American Urogynecologic Society. American Urogynecologic Society consensus statement: cystoscopy at the time of prolapse repair. Female Pelvic Med Reconstr Surg. 2018;24:258–259; reaffirmed 2021. doi:10.1097/SPV.0000000000000529. Full statement.